ANTIPHOSPHOLIPID ANTIBODIES, THEIR PATHOGENETIC AND DIAGNOSTIC ISSUES OBSTETRIC PRACTICE
Abstract
Not only thrombotic, but also “non-thrombotic” mechanisms of antiphospholipid antibodies are being actively studied in regard to their impact on the structure of reproductive losses and other complications of pregnancy. Non-thrombotic effects of APA include the damage of cells, the induction of apoptosis, the inhibition of proliferation, the suppression of human chorionic gonadotropin, the interference to the invasion of the trophoblast, and defects
of differentiation of the endometrium. Thrombotic effects are: widespread thrombosis, placental infarction, disruption of the annexin barrier, and anti-b2GPI and APC resistance.
of differentiation of the endometrium. Thrombotic effects are: widespread thrombosis, placental infarction, disruption of the annexin barrier, and anti-b2GPI and APC resistance.
About the Authors
V. O. Bitsadze
First Moscow State Medical Sechenov University of the Ministry of Health Russian Federation
Russian Federation
Russian Federation
D. Kh. Khizroeva
First Moscow State Medical Sechenov University of the Ministry of Health Russian Federation
Russian Federation
Russian Federation
N. A. Makatsariya
First Moscow State Medical Sechenov University of the Ministry of Health Russian Federation
Russian Federation
Russian Federation
E. S. Egorova
First Moscow State Medical Sechenov University of the Ministry of Health Russian Federation
Russian Federation
Russian Federation
S. M. Baymuradova
First Moscow State Medical Sechenov University of the Ministry of Health Russian Federation
Russian Federation
Russian Federation
T. Ya. Mashkova
First Moscow State Medical Sechenov University of the Ministry of Health Russian Federation
Russian Federation
Russian Federation
References
1. APASS Investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with Ischemic Stroke. JAMA. 2004; 291: 576-584.
2. Asherson R.A., Cervers R., Piette J.C., Shoenfeld Y. The antiphospholipid syndrome II. Autoimmune thrombosis. Netherlands. 2002; 457 p.
3. Bianchi V., Robles R., Alberio L., Furlan M., Lämmle B. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood. 2002 Jul 15; 100 (2): 710-3.
4. Cojocaru I.M., Cojocaru M., Musuroi C., Botezat M. Study of anti-cardiolipin and antibeta2-glycoprotein I antibodies in patients with ischemic stroke. Rom. J. Intern. Med. 2003; 41 (2): 189-204.
5. Franchini M., Montagnana M., Targher G., Lippi G. Reduced von Willebrand factor-cleaving protease levels in secondary thrombotic microangiopathies and other diseases. Semin Thromb Hemost. 2007 Nov; 33 (8): 787-97.
6. Galli M., Barbui T. Antiphospholipid antibodies and thrombosis: strength of association. Hematol J. 2003; 4 (3): 180-6.
7. Holers V.M., Girardi G., Mo L. et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J. Exp. Med. 2002 Jan 21; 195 (2): 211-20.
8. Khamashta M.A., Cuadrado M.J., Mujic F., Taub N.A., Hunt B.J., Hughes G.R. The management of thrombosis in the antiphospholipid-antibody syndrome. N. Engl. J. Med. 1995 Apr 13; 332 (15): 993-7.
9. Khamashta. Hughes Syndrome Antiphospholipid syndrome. London: Springer-Verlag. 2006; 15: 181.
10. Kim Y.U., Kinoshita T, Molina H, Hourcade D, Seya T, Wagner LM, Holers VM. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decayaccelerating factor and membrane cofactor protein. J Exp Med. 1995 Jan 1; 181 (1): 151-9.
11. Kitchens С S. Thrombotic storm: when thrombosis begets thrombosis. Amer. J. Med. 1998; 104 (4): 381-5.
12. Levy G.G., Nichols W.C., Lian E.C., Foroud T., McClintick J.N., McGee B.M., Yang A.Y., Siemieniak D.R., Stark K.R., Gruppo R., Sarode R., Shurin S.B., Chandrasekaran V., Stabler S.P., Sabio H., Bouhassira E.E., Upshaw J.D. Jr., Ginsburg D., Tsai H.M. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001 Oct 4; 413 (6855): 488-94.
13. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., Derksen R.H., DE Groot P.G., Koike T., Meroni P.L., Reber G., Shoenfeld Y., Tincani A., Vlachoyiannopoulos P.G., Krilis S.A. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb; 4 (2): 295-306.
14. Ortel T., Kitchens C., Pericak-Vance M., Erkan D., James A., Kulkarni R., Brandao L., Hahn S., Vance J. Thrombotic storm: a severe, rapidly progressive thrombotic disorder. Lupus. 2010; 19 (4): 524.
15. Petri M. Update on anti-phospholipid antibodies in SLE: the Hopkins’ Lupus Cohort. Lupus. 2010; 19 (4): 419-23.
16. Rand J.H., Wu X.X., Quinn A.S., Taatjes D.J. The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. Lupus. 2010; 19 (4): 460-9.
17. Schulman S., Svenungsson E., Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am. J. Med. 1998 Apr; 104 (4): 332-8.
18. Tincani A., Andreoli L., Casu C., Cattaneo R., Meroni P. Antiphospholipid antibody profile: implications for the evaluation and management of patients. Lupus. 2010; 19 (4): 432-5.
19. Vora S.K., Asherson R.A., Erkan D. Catastrophic antiphospholipid syndrome. J. Intensive Care Med. 2006; 21: 144-159.
For citation:
Bitsadze V.O., Khizroeva D.K., Makatsariya N.A., Egorova E.S., Baymuradova S.M., Mashkova T.Y. ANTIPHOSPHOLIPID ANTIBODIES, THEIR PATHOGENETIC AND DIAGNOSTIC ISSUES OBSTETRIC PRACTICE. Obstetrics, Gynecology and Reproduction. 2014;8(2):39-60. (In Russ.)
Views: 162
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 